Trials / Terminated
TerminatedNCT01982071
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Astellas Pharma China, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micafungin | Intravenous (IV) |
Timeline
- Start date
- 2013-09-26
- Primary completion
- 2015-08-28
- Completion
- 2015-08-28
- First posted
- 2013-11-13
- Last updated
- 2024-11-20
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01982071. Inclusion in this directory is not an endorsement.